Pharmacokinetic evaluation of ambrisentan

被引：15

作者：

Buckley, Mitchell S. ^{[2
]}

Wicks, Laura M. ^{[2
]}

Staib, Robin L. ^{[2
]}

Kirejczyk, Anna K. ^{[2
]}

Varker, Andrew S. ^{[2
]}

Gibson, Jamie J. ^{[3
,4
]}

Feldman, Jeremy P. ^{[1
]}

机构：

[1] Arizona Pulm Specialists Ltd, Phoenix, AZ 85012 USA

[2] Banner Good Samaritan Med Ctr, Dept Pharm, Phoenix, AZ 85006 USA

[3] St Josephs Hosp, Phoenix, AZ 85013 USA

[4] Med Ctr, Dept Pharm, Phoenix, AZ 85013 USA

来源：

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | 2011年 / 7卷 / 03期

关键词：

PULMONARY ARTERIAL-HYPERTENSION; ENDOTHELIN RECEPTOR ANTAGONISTS; BOSENTAN THERAPY; DOUBLE-BLIND; INHALED ILOPROST; OPEN-LABEL; COMBINATION; SILDENAFIL; SITAXSENTAN; MULTICENTER;

D O I：

10.1517/17425255.2011.557181

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Areas covered: This review focuses on, and critically appraises, the clinical efficacy and safety of ambrisentan as well as its pharmacokinetic and pharmacodynamic properties. The article also gives an expert perspective on the role of ambrisentan in the management of PAH. Expert opinion: Ambrisentan is an effective and safe treatment which is, in the authors' opinion, a valuable addition to the armamentarium against PAH. Ambrisentan offers a relative lack of drug interactions, once daily dosing and reassuring liver safety, offering safety and convenience advantages over bosentan. Presently, there is a lack of comparative studies between PDE5 inhibitors and endothelin receptor antagonists and a lack of data comparing bosentan with ambrisentan. This is hindering data-based conclusions regarding relative efficacy and further studies are needed to define the role of ambrisentan in the management of PAH.

引用

页码：371 / 380

页数：10

共 54 条

[1]

*ACT PHARM US INC, 2009, TRACL BOS PACK INS

[2]

[Anonymous], EFFECTS COMBINATION

[3]

[Anonymous], COCHRANE DATABASE SY

[4] Medical therapy for pulmonary arterial hypertension - Updated ACCP evidence-based clinical practice guidelines [J].

Badesch, David B. ;

Abman, Steven H. ;

Simonneau, Gerald ;

Rubin, Lewis J. ;

McLaughlin, Vallerie V. .

CHEST, 2007, 131 (06) :1917-1928

[5] Sitaxsentan therapy for pulmonary arterial hypertension [J].

Barst, RJ ;

Langleben, D ;

Frost, A ;

Horn, EM ;

Oudiz, R ;

Shapiro, S ;

McLaughlin, V ;

Hill, N ;

Tapson, VF ;

Robbins, IM ;

Zwicke, D ;

Duncan, B ;

Dixon, RAF ;

Frumkin, LR .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447

[6] Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan [J].

Barst, Robyn J. ;

Langleben, David ;

Badesch, David ;

Frost, Adaani ;

Lawrence, E. Clinton ;

Shapiro, Shelley ;

Naeije, Robert ;

Galie, Nazzareno .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) :2049-2056

[7] Updated Evidence-Based Treatment Algorithm in Pulmonary Arterial Hypertension [J].

Barst, Robyn J. ;

Gibbs, J. Simon R. ;

Ghofrani, Hossein A. ;

Hoeper, Marius M. ;

McLaughlin, Vallerie V. ;

Rubin, Lewis J. ;

Sitbon, Olivier ;

Tapson, Victor F. ;

Galie, Nazzareno .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2009, 54 (01) :S78-S84

[8] Sitaxsentan for the Treatment of Pulmonary Arterial Hypertension A 1-Year, Prospective, Open-Label Observation of Outcome and Survival [J].

Benza, Raymond L. ;

Barst, Robyn J. ;

Galie, Nazzareno ;

Frost, Adaani ;

Girgis, Reda E. ;

Highland, Kristin B. ;

Strange, Charlie ;

Black, Carol M. ;

Badesch, David B. ;

Rubin, Lewis ;

Fleming, Thomas R. ;

Naeije, Robert .

CHEST, 2008, 134 (04) :775-782

[9] Long-Term Outcomes With Ambrisentan Monotherapy in Pulmonary Arterial Hypertension [J].

Blalock, Shannon E. ;

Matulevicius, Susan ;

Mitchell, Laura C. ;

Reimold, Sharon ;

Warner, John ;

Peshock, Ronald ;

Torres, Fernando ;

Chin, Kelly M. .

JOURNAL OF CARDIAC FAILURE, 2010, 16 (02) :121-127

[10]

Cartin-Ceba R, 2010, CHEST

← 1 2 3 4 5 6 →